DYAI vs CDXS vs GEVO vs TWST vs SEER

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -8. 1% for Seer, Inc. (SEER). Analysts rate Codexis, Inc. (CDXS) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Twist Bioscience Corporation (TWST) delivered a total return of -49.

9%, compared to -95. 1% for Seer, Inc. (SEER). Over 10 years, the gap is even starker: TWST returned +318. 1% versus GEVO's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Seer, Inc.

(SEER) is the lower-risk stock at 0. 84β versus Twist Bioscience Corporation's 2. 47β — meaning TWST is approximately 194% more volatile than SEER relative to the S&P 500. On balance sheet safety, Seer, Inc. (SEER) carries a lower debt/equity ratio of 8% versus 2% for Dyadic International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus -8. 1% for Seer, Inc. (SEER). On earnings-per-share growth, the picture is similar: Twist Bioscience Corporation grew EPS 63. 9% year-over-year, compared to -3. 0% for Seer, Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Twist Bioscience Corporation (TWST) is the more profitable company, earning -20.

6% net margin versus -620. 9% for Seer, Inc. — meaning it keeps -20. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEVO leads at -11. 7% versus -717. 7% for SEER. At the gross margin level — before operating expenses — CDXS leads at 79. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Seer, Inc.

(SEER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84)). Codexis, Inc. (CDXS) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SEER: -96. 7%, CDXS: -19. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DYAI (Healthcare) and CDXS (Healthcare) and GEVO (Basic Materials) and TWST (Healthcare) and SEER (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DYAI is a small-cap high-growth stock; CDXS is a small-cap high-growth stock; GEVO is a small-cap high-growth stock; TWST is a small-cap high-growth stock; SEER is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.